ĀÜĄņĀŅĀ×

Eli Casdin founded Casdin Capital in 2011 after nearly ten years spent focused on disruptive technologies and business models in life sciences and healthcare, including authoring the black book, The Dawn of Molecular Medicine. Casdin Capitalā€™s combination of long-term vision and strong industry relationships keep it focused on the big picture yet nimble, while maintaining a consistent approach: Take aim at big markets; Invest in great ideas and great teams; Stay focused; Avoid hubris.

Prior to founding Casdin Capital, Eli was a Vice President and Analyst at Alliance Bernstein and a member of its ā€œthematicā€ based investment group, responsible for researching and investing in the implications of new technologies for the life science and healthcare sectors. Eliā€™s early experience includes time at Bear Stearns and at Cooper Hill Partners, one of the earliest biotechnology focused investment firms.

Eli earned his B.S. from Columbia University and his MBA from Columbia Business School and serves on the Columbia University School of GS Board of Directors. He also serves on the Board of Directors for the New York Genome Center, Exact Sciences, Prominex Dx, Genomatica, and Tenaya Therapeutics as well as participating as a board observer of several early stage therapeutic companies.